Vicente Alonso-Orduña

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Jaafar Bennouna, Javier Sastre, Dirk Arnold et al. · The Lancet Oncology · 2012 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +10

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Stefan Kubicka, Richard Greil, Thierry André et al. · Annals of Oncology · 2013 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Prognostic Factors and Long-Term Outcome of Pancreatic Neuroendocrine Neoplasms: Ki-67 Index Shows a Greater Impact on Survival than Disease Stage. The Large Experience of the Spanish National Tumor Registry (RGETNE)

Elena Martín‐Pérez, Jaume Capdevila, Daniel Castellano et al. · Neuroendocrinology · 2013 · 72 citations · Full text

Medicine, Oncology, Surgery +17

Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma

Carlos Fernández-Martos, Carles Pericay, Ferrán Losa et al. · JAMA Oncology · 2019 · 49 citations · Full text

Medicine, Oncology, Surgery +17

Phase II Trial of Preoperative Irinotecan–Cisplatin Followed by Concurrent Irinotecan–Cisplatin and Radiotherapy for Resectable Locally Advanced Gastric and Esophagogastric Junction Adenocarcinoma

Fernando Rivera, Maica Galán, Josep Tabernero et al. · International Journal of Radiation Oncology*Biology*Physics · 2009 · 35 citations

Medicine, Oncology, Surgery +17